title: Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas.
abstract: Etanidazole was developed as an oxygen-mimetic radiosensitizer less lipophilic than misonidazole. Sensitization depends on an adequate concentration of drug in the tumor at the time of irradiation. Therefore, due to the presence of the blood-brain barrier, brain tumors may theoretically be difficult to radiosensitize due to the hydrophilic characteristics of etanidazole. Based on previous reports of loss of BBB integrity in brain tumors, we investigated the ability of etanidazole to penetrate into malignant gliomas of patients receiving etanidazole as part of a Phase I continuous infusion protocol. The patients had completed previous external beam irradiation. Twenty-two patients were studied and their etanidazole plasma and biopsy data were compared to the 2-compartment model derived from a second group of 19 patients with bolus etanidazole. Etanidazole concentration in brain tumor biopsies varied widely and appeared to be clustered into a higher and a lower pharmacokinetic group having mean tumor to well-perfused second compartment ratios of 1 and 0.25, respectively. Both high and low etanidazole concentrations were evident in different biopsies obtained from the same patient. Correlations between histology and tissue concentrations suggested that the higher level correspond to malignant tissue. These data indicate that the blood brain barrier is disrupted to varying degrees by the brain tumor and/or prior irradiation and that etanidazole penetrates into brain tumors.
authors.affiliation: Joint Center of Radiation Therapy, Harvard Medical School, Boston, MA 02115.
authors.forename: S J
authors.initials: SJ
authors.lastname: Hurwitz
authors.forename: C N
authors.initials: CN
authors.lastname: Coleman
authors.forename: N
authors.initials: N
authors.lastname: Riese
authors.forename: J S
authors.initials: JS
authors.lastname: Loeffler
authors.forename: E
authors.initials: E
authors.lastname: Alexander
authors.forename: L
authors.initials: L
authors.lastname: Buswell
authors.forename: T Y
authors.initials: TY
authors.lastname: Neben
authors.forename: L
authors.initials: L
authors.lastname: Shargel
authors.forename: R A
authors.initials: RA
authors.lastname: Kramer
mesh_terms: D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D017341:Etanidazole; D006801:Humans; D007262:Infusions, Intravenous; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013997:Time Factors
chemical_list: D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D017341:Etanidazole